Altimmune Q2 net loss $16.1M; pemvidutide obesity trial data expected Q4 2023

Altimmune, Inc.

2023-Q2 EPS reported -$0.72 revenue$27,000

Net loss of $16.1M ($0.32/share) vs $20.1M ($0.42/share) in Q2 2022.
Cash, equivalents & short-term investments totaled $160.0M as of June 30, 2023.
R&D expenses $13.3M, G&A $4.8M for the quarter.
Top-line 48-week MOMENTUM Phase 2 obesity trial results expected Q4 2023.
Enrollment commenced in IMPACT Phase 2b NASH trial; top-line data expected Q1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Altimmune, Inc. reported the three months ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was $16.1 million, or $0.32 net loss per share, EPS $0.32 net loss per share.

Period: the three months ended June 30, 2023
Net income: Net loss for the three months ended June 30, 2023 was $16.1 million, or $0.32 net loss per share
EPS: $0.32 net loss per share
Result: reported results

Exact text from the filing

Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended June 30, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-23-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.